Moderna's decision not to diversify outside of COVID has hurt its business substantially. The company is still generating ...

Moderna, Inc. remains under pressure in 2025, despite recent next-gen COVID vaccine approval & cancer vaccine trial. Learn ...

Moderna faces significant uncertainty ahead of Q3 earnings, with heavy reliance on COVID vaccine revenues and limited ...

Over the past five years, 800 million people worldwide have been infected with COVID-19. The death toll has reached 7 million. Even now, deaths continue to occur. COVID-19 is now trending toward ...

Moderna has shared some of the phase 1/2 data that persuaded it to expand and p | Moderna has shared some of the phase 1/2 ...

Moderna’s mRNA-4359, when used with Keytruda, achieves a 24% overall objective response rate in patients with melanoma, with ...

In August, the U.S. Food and Drug Administration approved the new COVID-19 booster shots, but with certain restrictions.

Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groups Clinical findings reinforce preclinical data ...

Moderna has opened its new vaccine manufacturing and R&D facility in Oxfordshire, UK, the Moderna Innovation and Technology Centre (MITC).

A school district balked at the request for the Supreme Court to micromanage California’s schools’ health policy on the ...

Covid-19 infections continue to climb nationwide. And while updated vaccines are available, there is growing confusion over ...

Health experts are on the verge of possibly having two COVID-19 vaccines and ABC13 has learned how the two compare. SEE RELATED STORY: US COVID-19 vaccinations ramp up as Moderna shot nears ...